Publisher: John Wiley & Sons Inc
E-ISSN: 1879-0844|17|4|442-452
ISSN: 1388-9842
Source: EUROPEAN JOURNAL OF HEART FAILURE, Vol.17, Iss.4, 2015-04, pp. : 442-452
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
BackgroundHeart failure (HF) pharmacotherapy is often not prescribed according to guidelines. This longitudinal study investigated prescription rates and dosages of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB), beta‐blockers, and mineralocorticoid receptor antagonists (MRA), and concomitant changes of symptoms, echocardiographic parameters of left ventricular (LV) function and morphology and results of the Short Form‐36 (SF‐36) Health Survey in participants of the Interdisciplinary Network Heart Failure (INH) programme.Methods and resultsThe INH study evaluated a nurse‐coordinated management, HeartNetCare‐HFTM (HNC), against Usual Care (UC) in patients hospitalized for decompensated HF [LV ejection fraction (LVEF) ≤40% before discharge). A total of 706 subjects surviving >18 months (363 UC, 343 HNC) were examined 6‐monthly. At baseline, 92% received ACEi/ARB, (HNC/UC 91/93%, P = 0.28), 86% received beta‐blockers (86/86%, P = 0.83), and 44% received MRA (42/47%, P = 0.07). After 18 months, beta‐blocker use had increased only in HNC (+7.6%, P < 0.001). Guideline‐recommended target doses were achieved more frequently in HNC for ACEi/ARB (HNC/UC: 50/25%, P < 0.001) and beta‐blockers (39/15%, P < 0.001). The following variables were more improved and/or better in subjects undergoing HNC compared with UC: LVEF (47 ± 12 vs. 44 ± 12%, P = 0.004, change +17/+14%, P = 0.010), LV end‐diastolic diameter (59 ± 9 vs. 61 ± 9.6 mm, P = 0.024, change −2.3/–1.4mm, P = 0.13), New York Heart Association class (1.9 ± 0.7 vs. 2.1 ± 0.7, P = 0.001, change −0.44/–0.25, P = 0.002) and SF‐36 physical component summary score (41.6 ± 11.2 vs. 38.5 ± 11.8, P = 0.004, change +3.3 vs. +1.1 score points, P < 0.02).ConclusionsPrescription rates and dosages of ACEi/ARB and beta‐blockers improved more in HNC than UC patients. Concomitantly, participation in HNC was associated with significantly better clinical outcomes and more favourable echocardiographic changes after 18 months.
Related content
Quality of life and patient‐reported outcomes
BRITISH JOURNAL OF SURGERY, Vol. 105, Iss. 3, 2018-02 ,pp. :
Cardiology in the Young, Vol. 27, Iss. 3, 2016-05 ,pp. :